Current Fungal Infection Reports

, Volume 6, Issue 3, pp 178–191 | Cite as

Azole-Resistant Invasive Aspergillosis: Relationship to Agriculture

  • Christen Rune Stensvold
  • Lise Nistrup Jørgensen
  • Maiken Cavling Arendrup
Clinical Lab Issues (M Pfaller, Section Editor)

Abstract

Azole resistance in Aspergillus fumigatus has been increasingly reported particularly over the last decade. Two routes of acquisition are described: selection of resistance during long term azole therapy in the clinical setting, and primary acquisition of resistant isolates from the environment due to the considerable use of azole fungicides in agriculture and for material preservation. Three specific resistance genotypes have been found in azole naïve patients. Two of these have also been found in the environment and are characterized by a tandem repeat in the promoter region of the target gene coupled with point mutation(s) in CYP51A (TR34/L98H and TR46/Y121F/T289A). In the third a single target enzyme alteration (G432S) is found. These resistant “environmental” strains have been detected in many West-European countries as well as in the Asia-Pacifics. Noticeably, these two continents account for the highest fungicide use in the global perspective (37 % and 24 %, respectively). Among the 25 azole fungicides, five have been associated with the potential to select for the TR34/L98H genotype; three of these are among those most frequently used. Although the number of antifungal fungicide compounds and classes available is impressive compared to the armamentarium in human medicine, azoles will remain the most important group in agriculture due to superior field performance and significant resistance in fungal pathogens to other compounds. Hence, further spread of environmental resistant Aspergillus genotypes may occur and will depend on the fitness of each resistant phenotype and the pattern of azole fungicide use.

Keywords

Azole resistance Aspergillus Fungicide Agriculture CYP51 

Notes

Disclosure

Dr. M.C. Arendrup has received research grants from Astellas, Gilead, MSD and Pfizer, been advisor or consultant for Gilead, MSD and Pfizer and received speakers honorarium for talks from Astellas, Gilead, MSD and Pfizer.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Denning DW, Perlin DS. Azole resistance in Aspergillus: a growing public health menace. Future Microbiol. 2011;6:1229–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Lortholary O, Gangneux JP, Sitbon K, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect. 2011;17:1882–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.PubMedCrossRefGoogle Scholar
  5. 5.
    Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant. 2011;46:709–18.PubMedCrossRefGoogle Scholar
  6. 6.
    Snelders E, Melchers WJ, Verweij PE. Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis? Future Microbiol. 2011;6:335–47.PubMedCrossRefGoogle Scholar
  7. 7.
    •• Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52:1123–9. Study comparing diagnostic sensitivity by PCR and culture of Aspergillus in patients with IPA (22 BAL samples), ABPA (19 sputum samples) and CPA (42 sputum samples). Significantly more patients are found positive by PCR, however, on the cost of a positive rate of a third among 11 BAL samples from healthy volunteers. Remarkably, using a very sensitive nested PCR format amplifying the CYP51A gene, as many as 55 % were found to harbor resistance mutations. If confirmed this raises obvious concerns for current diagnostic procedures.PubMedCrossRefGoogle Scholar
  8. 8.
    van der Linden J, Arendrup M, Verweij P, SCARE-Network: Prospective International Surveillance of Azole Resistance (AR) in Aspergillus fumigatus (Af) (SCARE-Network). 51th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, USA, 2011: Abstract M-490.Google Scholar
  9. 9.
    Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373–9.PubMedCrossRefGoogle Scholar
  10. 10.
    van der Linden JW, Jansen RR, Bresters D, et al. Azole-resistant central nervous system aspergillosis. Clin Infect Dis. 2009;48:1111–3.PubMedCrossRefGoogle Scholar
  11. 11.
    • Howard SJ, Cerar D, Anderson MJ, et al. Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15:1068–76. Thorough study demonstrating the huge variety of different mutations and other mechanisms present in a cohort of azole exposed patients with chronic forms of aspergillosis in Manchester, UK.PubMedCrossRefGoogle Scholar
  12. 12.
    • Arendrup MC, Bille J, Dannaoui E, Ruhnke M, Heussel CP, Kibbler C. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant. In Press; doi:10.1038/bmt.2011.246. Official ELIC document offering detailed guidelines on how and when to perform and interpret culture, susceptibility testing and imaging diagnostics approached for patients at risk of fungal infections.
  13. 13.
    Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol. 2011;49 Suppl 1:S90–5.PubMedCrossRefGoogle Scholar
  14. 14.
    •• Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW, The European Committee on Antimicrobial Susceptibilty Testing Subcommittee on Antifungal Testing (EUCAST-AFST). EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Clin Microbiol Infect. In Press; doi:10.1111/j.1469-0691.2012.03890.x. First official breakpoints for Aspergillus species.
  15. 15.
    Lamb D, Kelly D, Kelly S. Molecular aspects of azole antifungal action and resistance. Drug Resist Updat. 1999;2:390–402.PubMedCrossRefGoogle Scholar
  16. 16.
    Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol Med. 2002;8:76–81.PubMedCrossRefGoogle Scholar
  17. 17.
    • Albarrag AM, Anderson MJ, Howard SJ, et al. Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. Antimicrob Agents Chemother. 2011;55:5113–21. Elegant study examining the underlying resistance mechanisms in isolates from two azole exposed patients. Various point mutations, a transposon inserted in the promoter in an isolate with up-regulated target enzyme level and efflux mediated resistance is found illustrating the multiple ways by which Aspergillus may escape azole treatment.PubMedCrossRefGoogle Scholar
  18. 18.
    Warrilow AG, Melo N, Martel CM, et al. Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B. Antimicrob Agents Chemother. 2010;54:4225–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Hu W, Sillaots S, Lemieux S, et al. Essential gene identification and drug target prioritization in Aspergillus fumigatus. PLoS Pathog. 2007;3:e24.PubMedCrossRefGoogle Scholar
  20. 20.
    • Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJ. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother. 2010;54:2425–30. This study includes almost 3000 A. fumigatus isolates collected in NL between 1994–2008. Results include a) dominance of the TR 34 /L98H resistant genotype among resistant isolates, b) demonstration of a variety of other non-synonomous mutations, and c) utility of a Cyp51A protein homology model to correlate individual mutations to their potential role for azole susceptibility.PubMedCrossRefGoogle Scholar
  21. 21.
    • Snelders E, Karawajczyk A, Verhoeven RJ, et al. The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol. 2011;48:1062–70. Molecular dynamics simulations combined with site-directed mutagenesis of amino acid substitutions in the CYP51A gene demonstrate that both the L98H substitution and the 34 bp TR are needed to obtain the multi-azole resistant phenotype.PubMedCrossRefGoogle Scholar
  22. 22.
    Mellado E, Garcia-Effron G, Alcázar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007;51:1897–904.PubMedCrossRefGoogle Scholar
  23. 23.
    Snelders E, Veld RA Huis In’t, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009;75:4053–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Arendrup MC, Mavridou E, Mortensen KL, et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One. 2010;5:e10080.PubMedCrossRefGoogle Scholar
  25. 25.
    Tashiro M, Izumikawa K, Minematsu A, et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother. 2012;56:584–7.PubMedCrossRefGoogle Scholar
  26. 26.
    • Bueid A, Howard SJ, Moore CB, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother. 2010;65:2116–8. Follow up study on the Manchester cohort of patients with chronic forms of aspergillosis, demonstrating an increasing resistance rate and as many as 40 % due to other mechanisms than target gene mutations illustrating the complexity of resistance in the azole exposed patient population with respect to treatment and challenges for future molecular resistance detection in this particular setting.PubMedCrossRefGoogle Scholar
  27. 27.
    Camps SM, van der Linden JW, Li Y, et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother. 2012;56:10–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Chen J, Li H, Li R, Bu D, Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother. 2005;55:31–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Dannaoui E, Borel E, Monier MF, Piens MA, Picot S, Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother. 2001;47:333–40.PubMedCrossRefGoogle Scholar
  30. 30.
    Bellete B, Raberin H, Morel J, Flori P, Hafid J, Manhsung RT. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med Mycol. 2010;48:197–200.PubMedCrossRefGoogle Scholar
  31. 31.
    •• Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356:1481–3. First report on the TR 34 /L98H genotype.PubMedCrossRefGoogle Scholar
  32. 32.
    Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219.PubMedCrossRefGoogle Scholar
  33. 33.
    •• Mortensen KL, Jensen RH, Johansen HK, et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol. 2011;49:2243–51. First report on TR 34 /L98H in CF patients. Genotyping suggested selection for resistance in the patient as well as resistance being achieved in the environment as 1) susceptible and resistant isolates (not involving TR 34 /L98H isolates) with identical or very closely related genotypes (two patients), and 2) two related susceptible isolates and a third unrelated resistant isolate with a unique genotype and the TR/L98H resistance combination (one patient) were found.PubMedCrossRefGoogle Scholar
  34. 34.
    • Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother. 2011;55:4465–8. First report on TR 34 /L98H in China.PubMedCrossRefGoogle Scholar
  35. 35.
    • Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother. 2012;67:362–6. First report on TR 34 /L98H in India.PubMedCrossRefGoogle Scholar
  36. 36.
    • Mortensen KL, Mellado E, Lass-Flörl C, Rodriguez-Tudela JL, Johansen HK, Arendrup MC. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother. 2010;54:4545–9. First report demonstrating the TR 34 /L98H genotype in the environment outside the Netherlands.PubMedCrossRefGoogle Scholar
  37. 37.
    •• Snelders E, Camps SM, Karawajczyk A, et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One. 2012;7:e31801. This study provides data suggesting five specific agricultural fungicides are the most important candidates responsible for selecting azole resistance in Aspergillus. Furthermore, one of these are shown to be able to induce a tandem repeat in the promoter region of the target gene thus adding further support to the link between agricultural fungicides and resistance in Aspergillus.PubMedCrossRefGoogle Scholar
  38. 38.
    Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis. 2009;9:789–95.PubMedCrossRefGoogle Scholar
  39. 39.
    O’Gorman CM, Fuller HT, Dyer PS. Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus fumigatus. Nature. 2009;457:471–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Klaassen CH, Gibbons JG, Fedorova ND, Meis JF, Rokas A. Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogen Aspergillus fumigatus. Mol Ecol. 2012;21:57–70.PubMedCrossRefGoogle Scholar
  41. 41.
    Mavridou E, Meletiadis J, Jancura P, et al. Association of in vitro growth parameters with in vivo virulence of Aspergillus fumigatus based on a novel virulence index. 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 27th International Congress of Chemotherapy (ICC). Milan, Italy, 2011. Abstract P1768.Google Scholar
  42. 42.
    •• Kuipers S, Brüggemann RJ, de Sévaux RG, et al. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob Agents Chemother. 2011;55:3564–6. First and so far the only report on the second environmental azole resistant A. fumigatus with a combination of a tandem repeat and point mutations (TR 46 /Y121F/T289A).PubMedCrossRefGoogle Scholar
  43. 43.
    •• Alanio A, Cordonnier C, Bretagne S. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies-authors’ response. J Antimicrob Chemother. 2011;66:955–5. First report of the recovery of the azole resistant G432S genotype in an azole naïve patient suggesting this genotype may also derive from the environment.CrossRefGoogle Scholar
  44. 44.
    Leroux P, Walker AS. Multiple mechanisms account for resistance to sterol 14 alpha-demethylation inhibitors in field isolates of Mycosphaerella graminicola. Pest Manag Sci. 2011;67:44–59.PubMedCrossRefGoogle Scholar
  45. 45.
    Willger SD, Puttikamonkul S, Kim KH, et al. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog. 2008;4:e1000200.PubMedCrossRefGoogle Scholar
  46. 46.
    Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification. Antimicrob Agents Chemother. 2008;52:1244–51.PubMedCrossRefGoogle Scholar
  47. 47.
    Mellado E, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Role of Aspergillus lentulus 14-α sterol demethylase (Cyp51A) in azole drug susceptibility. Antimicrob Agents Chemother. 2011;55:5459–68.PubMedCrossRefGoogle Scholar
  48. 48.
    Alhambra A, Catalán M, Moragues MD, et al. Isolation of Aspergillus lentulus in Spain from a critically ill patient with chronic obstructive pulmonary disease. Rev Iberoam Micol. 2008;25:246–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Baddley JW, Marr KA, Andes DR, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009;47:3271–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Steinbach WJ, Benjamin DK, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis. 2004;39:192–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis. 2003;188:305–19.PubMedCrossRefGoogle Scholar
  52. 52.
    Koss T, Bagheri B, Zeana C, Romagnoli MF, Grossman ME. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J Am Acad Dermatol. 2002;46:945–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Seo K, Akiyoshi H, Ohnishi Y. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol Immunol. 1999;43:1017–25.PubMedGoogle Scholar
  54. 54.
    Hsueh PR, Lau YJ, Chuang YC, et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother. 2005;49:512–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Hachem RY, Kontoyiannis DP, Boktour MR, et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer. 2004;101:1594–600.PubMedCrossRefGoogle Scholar
  56. 56.
    Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses. 2002;45:406–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Mortensen KL, Johansen HK, Fuursted K, et al. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis. 2011;30:1355–63.PubMedCrossRefGoogle Scholar
  58. 58.
    • Arendrup MC, Jensen RH, Grift K, et al. In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration. J Infect Dis. In Press. First and so far only report on the role of CYP51A in acquired itraconazole resistance in A. terreus.Google Scholar
  59. 59.
    • Liu W, Sun Y, Chen W, Wan Z, Bu D, Li R. T778G mutation in cyp51C gene confers voriconazole-resistance in Aspergillus flavus causing aspergillosis. Antimicrob Agents Chemother. In Press; doi:10.1128/AAC.05477-11. First and so far only report on the role of CYP51C in acquired itraconazole resistance in A. flavus.
  60. 60.
    Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother. 2009;53:4514–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Howard SJ, Harrison E, Bowyer P, Varga J, Denning DW. Cryptic species and azole resistance in the Aspergillus niger complex. Antimicrob Agents Chemother. 2011;55:4802–9.PubMedCrossRefGoogle Scholar
  62. 62.
    Van Der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol. 2011;49 Suppl 1:S82–9.CrossRefGoogle Scholar
  63. 63.
    Oerke EC. Crop losses to pests. J Agric Sci. 2006;144:31–43.CrossRefGoogle Scholar
  64. 64.
    Kuck K-H, Leadbeater A, Gisi U. FRAC mode of action classification and resistance risk of fungicides. In: Modern crop protection compounds. Wiley-VCH Verlag GmbH & Co. KGaA; 2012. 539–57.Google Scholar
  65. 65.
    Russell PE. A century of fungicide evolution. J Agric Sci. 2005;143:11–25.CrossRefGoogle Scholar
  66. 66.
    Brent K, Holloman D. Fungicide resistance in crop pathogens: how can it be managed? In: FRAC Monograph 1. 2nd Ed. 2007. http://www.frac.info/frac/publication/anhang/FRAC_Mono2_2007.pdf. Accessed 25 May 2012.
  67. 67.
    Child RD, Evans DE, Allen J, Arnold GM. Growth-responses in oilseed rape (Brassica napus L.) to combined applications of the triazole chemicals triapenthenol and tebuconazole and interactions with gibberellin. Plant Growth Regul. 1993;13:203–12.CrossRefGoogle Scholar
  68. 68.
    Still JR, Pill WG. Growth and stress tolerance of tomato seedlings (Lycopersicon esculentum Mill.) in response to seed treatment with paclobutrazol. J Hortic Sci Biotechnol. 2004;79:197–203.Google Scholar
  69. 69.
    Jaleel CA, Gopi R, Manivannan P, Panneerselvam R. Responses of antioxidant defense system of Catharanthus roseus (L.) G. Don. to paclobutrazol treatment under salinity. Acta Physiol Plant. 2007;29:205–9.CrossRefGoogle Scholar
  70. 70.
    Bartlett DW, Clough JM, Godwin JR, Hall AA, Hamer M, Parr-Dobrzanski B. The strobilurin fungicides. Pest Manag Sci. 2002;58:649–62.PubMedCrossRefGoogle Scholar
  71. 71.
    Leroux P, Albertini C, Gautier A, Gredt M, Walker AS. Mutations in the CYP51 gene correlated with changes in sensitivity to sterol 14 alpha-demethylation inhibitors in field isolates of Mycosphaerelia graminicola. Pest Manag Sci. 2007;63:688–98.PubMedCrossRefGoogle Scholar
  72. 72.
    Fraaije BA, Butters JA, Coelho JM, Jones DR, Hollomon DW. Following the dynamics of strobilurin resistance in Blumeria graminis f.sp. tritici using quantitative allele-specific real-time PCR measurements with the fluorescent dye SYBR Green I. Plant Pathol. 2002;51:45–54.CrossRefGoogle Scholar
  73. 73.
    Jørgensen LN, Thygesen K. Fungicide resistance and its impact on recommendations to farmers – experiences from Denmark. Asp Appl Biol. 2006;78:65–70.Google Scholar
  74. 74.
    Avenot HF, Michailides TJ. Progress in understanding molecular mechanisms and evolution of resistance to succinate dehydrogenase inhibiting (SDHI) fungicides in phytopathogenic fungi. Crop Prot. 2010;29:643–51.CrossRefGoogle Scholar
  75. 75.
    Cools H, Fraaije B. Resistance to azole fungicides in Mycosphaerella graminicola: mechanisms and management. In: Thind T, editor. Fungicide resistance in crop protection: risk and management. Cambridge: CABI; 2012. p. 64–77.CrossRefGoogle Scholar
  76. 76.
    Schepers H. Fitness of isolates of Sphaerotheca fuliginea resistant or sensitive to fungicides which inhibit ergosterol biosynthesis. Neth J Plant Pathol. 1985;91:65–76.CrossRefGoogle Scholar
  77. 77.
    Eckert JW. Penicillium digitatum biotypes with reduced sensitivity to imazalil. Phytopathology. 1987;77:1728–8.Google Scholar
  78. 78.
    Heaney S. Population dynamics of DMI fungicide sensitivity changes in barley powdery mildew. In: Delp CJ, editor. Fungicide resistance in North America. St. Paul: ARS Press, American Phytopathological Society; 1988. p. 89–92.Google Scholar
  79. 79.
    Hildebrand PD, Lockhart CL, Newbery RJ, Ross RG. Resistance of Venturia inaequalis to bitertanol and other demethylation-inhibiting fungicides. Can J Plant Pathol. 1988;10:311–6.CrossRefGoogle Scholar
  80. 80.
    Kendall SJ, Hollomon DW, Cooke LR, Jones DR. Changes in sensitivity to DMI fungicides in Rhynchosporium secalis. Crop Prot. 1993;12:357–62.CrossRefGoogle Scholar
  81. 81.
    Gisi U, Pavic L, Stanger C, Hugelshofer U, Sierotzki H. Dynamics of Mycosphaerella graminicola populations in response to selection by different fungicides. In: Dehne H, Gisi U, Kuck K, Russell P, Lyr H, editors. Modern fungicides and antifungal compounds IV. Alton: BCPC; 2005. p. 89–101.Google Scholar
  82. 82.
    Clark W. Septoria tritici and azole performance. Fungicide resistance: are we winning the battle but losing the war? Asp Appl Biol. 2006;78:127–32.Google Scholar
  83. 83.
    Delye C, Bousset L, Corio-Costet MF. PCR cloning and detection of point mutations in the eburicol 14alpha-demethylase (CYP51) gene from Erysiphe graminis f.sp. hordei, a “recalcitrant” fungus. Curr Genet. 1998;34:399–403.PubMedCrossRefGoogle Scholar
  84. 84.
    Cools HJ, Fraaije BA. Are azole fungicides losing ground against Septoria wheat disease? Resistance mechanisms in Mycosphaerella graminicola. Pest Manag Sci. 2008;64:681–4.PubMedCrossRefGoogle Scholar
  85. 85.
    Fraaije BA, Cools HJ, Kim SH, Motteram J, Clark WS, Lucas JA. A novel substitution I381V in the sterol 14 alpha-demethylase (CYP51) of Mycosphaerella graminicola is differentially selected by azole fungicides. Mol Plant Pathol. 2007;8:245–54.PubMedCrossRefGoogle Scholar
  86. 86.
    Stammler G, Carstensen M, Koch A, Semar M, Strobel D, Schlehuber S. Frequency of different CYP51-haplotypes of Mycosphaerella graminicola and their impact on epoxiconazole-sensitivity and -field efficacy. Crop Prot. 2008;27:1448–56.CrossRefGoogle Scholar
  87. 87.
    Chassot C, Hugelshofer U, Sierotzki H, Gisi U. Sensitivity of CYP51 genotypes to DMI fungicides in Mycosphaerella graminicola. In: Dehne H, Deising H, Gisi U, Kuck K, Russell P, Lyr H, editors. Modern fungicides and antifungals compounds V. Braunschweig: DPG-Selbstverlag; 2008. p. 129–36.Google Scholar
  88. 88.
    Hamamoto H, Hasegawa K, Nakaune R, et al. Tandem repeat of a transcriptional enhancer upstream of the sterol 14 alpha-demethylase gene (CYP51) in Penicillium digitatum. Appl Environ Microbiol. 2000;66:3421–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Schnabel G, Jones AL. The 14alpha-demethylasse (CYP51A1) gene is overexpressed in Venturia inaequalis strains resistant to myclobutanil. Phytopathology. 2001;91:102–10.PubMedCrossRefGoogle Scholar
  90. 90.
    de Waard MA, Andrade AC, Hayashi K, Schoonbeek HJ, Stergiopoulos I, Zwiers LH. Impact of fungal drug transporters on fungicide sensitivity, multidrug resistance and virulence. Pest Manag Sci. 2006;62:195–207.PubMedCrossRefGoogle Scholar
  91. 91.
    Hayashi K, Schoonbeek HJ, De Waard MA. Modulators of membrane drug transporters potentiate the activity of the DMI fungicide oxpoconazole against Botrytis cinerea. Pest Manag Sci. 2003;59:294–302.PubMedCrossRefGoogle Scholar
  92. 92.
    Reimann S, Deising HB. Inhibition of efflux transporter-mediated fungicide resistance in Pyrenophora tritici-repentis by a derivative of 4 ′-hydroxyflavone and enhancement of fungicide activity. Appl Environ Microbiol. 2005;71:3269–75.PubMedCrossRefGoogle Scholar
  93. 93.
    Shaw MW. A model of the evolution of polygenically controlled fungicide resistance. Plant Pathol. 1989;38:44–55.CrossRefGoogle Scholar
  94. 94.
    Shaw M. Is there such a thing as a fungicide resistance strategy? A modeller’s perspective. Asp Appl Biol. 2006;78:37–43.Google Scholar
  95. 95.
    van den Bosch F, Paveley N, Shaw M, Hobbelen P, Oliver R. The dose rate debate: does the risk of fungicide resistance increase or decrease with dose? Plant Pathol. 2011;60:597–606.CrossRefGoogle Scholar
  96. 96.
    Verweij PE, Camps SM, Kema GH, Melchers WJ. Comment on: low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother. 2011;66:954–5.PubMedCrossRefGoogle Scholar
  97. 97.
    Lagrou K, De Vleeschouwer J, Meerseman W, Dupont L, Verleden G, Melchers W, et al. Triazole resistance among 229 clinical Aspergillus fumigatus isolates. 3rd Advances Against Aspergillosis Conference. Miami, Florida, USA, 2008. Abstract 33.Google Scholar
  98. 98.
    Burgel PR, Baixench MT, Amsellem M, et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother. 2012;56:869–74.PubMedCrossRefGoogle Scholar
  99. 99.
    • Morio F, Aubin GG, Danner-Boucer I, et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother. In Press; doi:10.1093/jac/dks160. This study demonstrates the clinical utility of the itraconazole screening agar for routine identification of potentially resistant isolates and furthermore detects a 6 % rate of TR 34 /L98H in a French cohort of CF patients.
  100. 100.
    •• Garcia-Effron G, Dilger A, Alcazar-Fuoli L, Park S, Mellado E, Perlin DS. Rapid detection of triazole antifungal resistance in Aspergillus fumigatus. J Clin Microbiol. 2008;46:1200–6. Description of a molecular assay for the detection of azole resistance due to the most commonly found alterations in the CYP51A gene (codon L98, M220 and G54 and G138).PubMedCrossRefGoogle Scholar
  101. 101.
    Bodey GP. Azole antifungal agents. Clin Infect Dis. 1992;14 Suppl 1:S161–9.PubMedCrossRefGoogle Scholar
  102. 102.
    Kelly SL, Lamb DC, Corran AJ, Baldwin BC, Kelly DE. Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol. Biochem Biophys Res Commun. 1995;207:910–5.PubMedCrossRefGoogle Scholar
  103. 103.
    Hodiamont CJ, Dolman KM, Ten Berge IJ, Melchers WJ, Verweij PE, Pajkrt D. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol. 2009;47:217–20.PubMedCrossRefGoogle Scholar
  104. 104.
    Nascimento AM, Goldman GH, Park S, et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother. 2003;47:1719–26.PubMedCrossRefGoogle Scholar
  105. 105.
    Slaven JW, Anderson MJ, Sanglard D, et al. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol. 2002;36:199–206.PubMedCrossRefGoogle Scholar
  106. 106.
    da Silva Ferreira ME, Capellaro JL, dos Reis Marques E, et al. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother. 2004;48:4405–13.PubMedCrossRefGoogle Scholar
  107. 107.
    Moore CB, Sayers N, Mosquera J, Slaven J, Denning DW. Antifungal drug resistance in Aspergillus. J Infect. 2000;41:203–20.PubMedCrossRefGoogle Scholar
  108. 108.
    Cannon RD, Lamping E, Holmes AR, et al. Efflux-mediated antifungal drug resistance. Clin Microbiol Rev. 2009;22:291–321.PubMedCrossRefGoogle Scholar
  109. 109.
    Manavathu EK, Vazquez JA, Chandrasekar PH. Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent. Int J Antimicrob Agents. 1999;12:213–9.PubMedCrossRefGoogle Scholar
  110. 110.
    Xiong Q, Hassan SA, Wilson WK, et al. Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors. Antimicrob Agents Chemother. 2005;49:518–24.PubMedCrossRefGoogle Scholar
  111. 111.
    Mowat E, Butcher J, Lang S, Williams C, Ramage G. Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J Med Microbiol. 2007;56:1205–12.PubMedCrossRefGoogle Scholar
  112. 112.
    Müller FM, Seidler M, Beauvais A. Aspergillus fumigatus biofilms in the clinical setting. Med Mycol. 2011;49 Suppl 1:S96–S100.PubMedCrossRefGoogle Scholar
  113. 113.
    Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. Our current understanding of fungal biofilms. Crit Rev Microbiol. 2009;35:340–55.PubMedCrossRefGoogle Scholar
  114. 114.
    Richie DL, Hartl L, Aimanianda V, et al. A role for the unfolded protein response (UPR) in virulence and antifungal susceptibility in Aspergillus fumigatus. PLoS Pathog. 2009;5:e1000258.PubMedCrossRefGoogle Scholar
  115. 115.
    Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003;47:1120–4.PubMedCrossRefGoogle Scholar
  116. 116.
    Mann PA, Parmegiani RM, Wei SQ, et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother. 2003;47:577–81.PubMedCrossRefGoogle Scholar
  117. 117.
    Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother. 2008;52:2468–72.PubMedCrossRefGoogle Scholar
  118. 118.
    Manavathu E, Baskaran I, Krishnan S, Alangaden G, Chandrasekar P. Cytochrome P450 14alpha-sterol demethylase mutation dependent triazole cross-resistance in Aspergillus fumigatus. 43rd interscience conference on antimicrobial agents and chemotherapy. Chicago, Illinois, USA. 2003: Abstract M-471.Google Scholar
  119. 119.
    Escribano P, Recio S, Peláez T, Bouza E, Guinea J. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. Antimicrob Agents Chemother. 2011;55:2460–2.PubMedCrossRefGoogle Scholar
  120. 120.
    van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007–2009. Emerg Infect Dis. 2011;17:1846–54.PubMedCrossRefGoogle Scholar
  121. 121.
    Arendrup MC, Perkhofer S, Howard SJ, et al. Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. Antimicrob Agents Chemother. 2008;52:3504–11.PubMedCrossRefGoogle Scholar
  122. 122.
    Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother. 2004;48:2747–50.PubMedCrossRefGoogle Scholar
  123. 123.
    Asano M, Kano R, Makimura K, Hasegawa A, Kamata H. Molecular typing and in-vitro activity of azoles against clinical isolates of Aspergillus fumigatus and A. niger in Japan. J Infect Chemother. 2011;17:483–6.PubMedCrossRefGoogle Scholar
  124. 124.
    Escribano P, Recio S, Peláez T, González-Rivera M, Bouza E, Guinea J. In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations. Antimicrob Agents Chemother. 2012;56:174–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Christen Rune Stensvold
    • 1
  • Lise Nistrup Jørgensen
    • 2
  • Maiken Cavling Arendrup
    • 1
  1. 1.Unit of Mycology and Parasitology, Department of Microbiological Surveillance and ResearchStatens Serum InstitutCopenhagenDenmark
  2. 2.Department of Integrated Pest Management, Faculty of Agricultural SciencesAarhus UniversitySlagelseDenmark

Personalised recommendations